On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Hereditary angioedema is characterized by unpredictable swelling involving the face, oropharynx, extremities, or abdomen, without hives or pruritus. Laryngeal attacks carry a risk of asphyxiation, ...

Discover a study in which the analysis demonstrated significant reductions in HAE attacks among adolescent patients.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, ...

The company is on track to complete enrollment in the global Phase 3 HAELO study for hereditary angioedema (HAE) by the third quarter of 2025 and has dosed the first patient in the Phase 3 ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Hereditary angioedema (HAE) is a genetic disorder that causes episodes of extreme swelling (angioedema), commonly in the face, hands, feet, digestive tract, or upper airways. Symptoms may begin ...

BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...

Ionis Pharmaceuticals Inc (IONS) reports a 10% revenue increase and raises 2025 guidance, driven by successful product ...

KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial ...